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Abstract
Heart failure (HF) is rapidly growing, conferring considerable mortality, morbidity, and costs. Dedicated HF clinics improve pa-
tient outcomes, and the development of a national HF clinics network aims at addressing this need at national level. Such a
network should respect the existing health care infrastructures, and according to the capacities of hosting facilities, it can
be organized into three levels. Establishing the continuous communication and interaction among the components of the net-
work is crucial, while supportive actions that can enhance its efficiency include involvement of multidisciplinary health care
professionals, use of structured HF-specific documents, such as discharge notes, patient information leaflets, and patient
booklets, and implementation of an HF-specific electronic health care record and database platform.
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The need for a heart failure network
Heart failure (HF) is the most rapidly growing cardiovascular
condition globally and is associated with considerable mortal-
ity, morbidity, and hospitalization rates.1 Patients hospital-
ized for HF have a particularly adverse prognosis, with a
high risk of mortality and rehospitalization and account for
approximately 70% of the total expenditure related to the
syndrome.2 As a result, HF is becoming a major challenge
for the health care systems.3 Several community-based stud-
ies and registries have consistently shown that evidence-
based therapies are underused in real-life HF patients, while
mortality and hospitalization rates are higher than those re-
ported in randomized clinical trials.4
Dedicated HF clinics have been developed in many coun-
tries to systematically address the unmet needs for timely di-
agnosis, management, and clinical follow-up of HF patients.5,6
A wide variety of multidisciplinary strategies to manage HF
patients have been examined including outpatient clinic-
based care, home-visiting programmes, structure telephone
support, telemonitoring, and patient education to enhance
self-care as compared with usual care.7 The optimal strategy
according to patient status has not been proved, but involve-
ment of a cardiologist in the care of HF patients improves
clinical outcomes.8 A multi-professional strategy for the man-
agement of HF patients has been shown to reduce all-cause
mortality and all-cause and HF hospitalizations and improved
adherence to life-saving medications.9 Structured telephone
support and non-invasive telemonitoring were also found to
reduce all-cause mortality and HF-related hospitalizations,
whereas home-visit programmes decreased primarily all-
cause and HF hospitalizations. Interestingly, follow-up in a
clinic with primary care supervision seems to be ineffective.7
Structure and functions of a national
heart failure clinics network
The development of a national HF clinics network aims at three
important aims: (i) the improvement of patient outcomes in
terms of mortality, hospitalization, and quality of life, (ii) the re-
duction of HF-related health care expenditure, and (iii) the im-
provement in the allocation of limited health care resources.
The network is expected to provide expert consultation, assess-
ment, and management to all patients with HF, including both
HF with reduced and preserved left ventricular ejection fraction.
Establishing a national HF clinics network faces major chal-
lenges concerning the incorporation of existing clinical man-
agement processes and the integration of medical units
providing different levels of care.5 In order for this network
to be realistic, applicable, and functional, it has to respect
the existing health care infrastructures, on which is expected
to run. This aim would be better served if the HF network is or-
ganized into a three-level structure according to capacities of
the hosting health care facility.5 The main characteristics and
requirements of this three-level structure are summarized in
Table 1. A similar graded structure of HF clinics is also pro-
posed by the Heart Failure Association (HFA) of the European
Society of Cardiology (ESC) a means to ensure quality care for
HF across Europe (M.F. Piepoli, personal communication).
The medical units serving at the first level of care will be
termed ‘HF clinics’. These units reside at regional or provincial
secondary hospitals through the country and consist of an out-
patient clinic providing regular patient follow-up linked to an in-
patient cardiology department providing care in case of
decompensation or acute de novo presentation (ward and gen-
eral intensive care unit). HF clinics are expected to provide basic
diagnostic and therapeutic services including clinical evaluation,
electrocardiography, 6 min walk test, quality of life assessment,
main haematological and biochemical investigations including
natriuretic peptides and cardiac troponins, and echocardio-
graphic imaging. In terms of personnel, HF clinics are populated
by specialized cardiologists, ideally including at least one cardiol-
ogist with HF training and a nurse with experience in HF. HF
clinic establishes affiliations with primary care units and physi-
cians of the same region in order to ensure a seamless referral
pathway of HF patients. HF clinics are further expected to con-
tribute to national and international HF registries.
The medical units serving at the second level of care are
termed ‘HF units’. These reside at larger secondary or tertiary
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hospitals covering the greater regions of the country with facil-
ities for cardiac devices and more advanced cardiac proce-
dures. In addition to the infrastructure and services provided
by HF clinics, HF units are hosted in hospitals that provide
more complex diagnostic and therapeutic procedures, includ-
ing cardiopulmonary exercise testing, cardiac catheterization
and electrophysiology (basic electrophysiology studies and de-
vice implantation), and computed tomography imaging, and
are further equipped with a cardiac care unit and optionally
with a cardiac magnetic resonance imaging lab or nuclear car-
diology lab and cardiac surgery. HF units are populated by car-
diologists with HF training and optionally with one HF expert
(cardiologist specialized in HF) and an HF nurse, collaborating
with other medical specialists such as nephrologist,
pulmonologists, or cardiac rehabilitation specialists. More-
over, HF units are expected to contribute to HF research at
least at a national level. HF units are further expected to con-
tribute to HF education and training by running regional edu-
cational events.
Finally, the medical units at the third level of care are
termed ‘HF centres’. These reside at large tertiary or univer-
sity hospitals in main urban areas of the country. In addition
to the infrastructure and services provided by hospitals
hosting HF units, those hosting HF centres provide high-end
diagnostic and therapeutic procedures, including cardiac
magnetic resonance, 3D echo imaging, nuclear cardiology, ad-
vanced electrophysiology, such as navigation systems and
ventricular tachycardia ablation, endomyocardial biopsy and
complex cardiac catheterization interventions such as trans-
catheter valve implantation or repair, mechanical circulatory
support, and cardiac surgery offering ventricular assist device
implantation and/or cardiac transplantation. The hosting hos-
pitals provide wards and cardiac care units with dedicated HF
beds and are populated by HF specialists with experience in
the different areas of advanced HF management, experi-
enced HF nurses, heart transplant/mechanical circulatory
support specialists and technicians, and other affiliated med-
ical specialists. HF centres further have a leading role in HF re-
search at national and international level. Finally, they also
hold a leading role in HF education and training.
In parallel to the aforementioned organizational structure,
it is important to ensure the establishment of continuous
communication, interaction, and networking among the dif-
ferent medical units that constitute the HF network. Impor-
tant supportive actions that may enhance the efficiency of
the network include the involvement of additional health
care personnel besides the treating physicians, with a central
role of HF nurses, the development and widespread use of
structured documents such as an HF-specific discharge note,
an HF patient information leaflet, and an HF patient booklet
as well as the development and implementation of a widely
accessible HF-specific electronic health care record and data-
base platform, as described in detail below. Further support
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training sessions originated from higher-level to lower-level
structures in the context of the network. The application of
widely accepted clinical protocols for diagnosis, treatment,
and follow-up as well as the training and accreditation of in-
volved health care professionals in HF would enhance consid-
erably efficiency. In addition, the performance of the units
should be assessed regularly based on outcome measures
or quality indicators such as mortality, readmissions and
emergency room visits, patients’ functional status, and
health-related quality of life (HR-QoL). At a later stage of de-
velopment, all medical units participating in the network will
be required to apply for accreditation for the level of services
that are expected to provide.
Heart failure is characterized by multisystem involvement,
and therefore, the formation of a multidisciplinary team able
to manage effectively the different aspects of HF health care
is important, particularly at the higher-level structures. Such
a multidisciplinary HF teamwould facilitate referral of patients
to specialists and allow joint consultation sessions with the
participation of two ormore specialists if this is deemed neces-
sary. Besides HF specialists, cardiologists, and HF nurses, this
team may consist of nephrologists, pulmonologists, psychia-
trists, psychologists, physiotherapists, and other specialists.
With the development of the HF network, the lower-level
structures will benefit from these multidisciplinary HF teams.
Exercise training and rehabilitation programmes constitute
an indispensable aspect of HF care. As this network is de-
signed to operate on the existing infrastructure, rehabilitation
services will be provided only by certain units where such ser-
vices are already available. A more extensive availability of
cardiac rehabilitation remains an unmet need that should
be addressed at a later stage of network development.
According to local or national needs, the network may also
comprise highly specialized clinics, including clinics for genetic
cardiomyopathies, cardiomyopathies associated with sys-
temic conditions such as sarcoidosis, cardio-oncology clinics,
cardiac clinics for haemoglobinopathies, or clinics for adults
with congenital heart disease.
Treatment and follow-up protocols
Heart failure treatment and follow-up strategies vary widely
across hospitals and clinics even within the same region.10–
12 There is therefore a need for implementation of structured
follow-up protocols. The optimal method of monitoring will
depend on local organizational structures and resources as
well as patient needs. Follow-up may involve regular visits
to community or hospital clinics, home visits or remote mon-
itoring with or without implanted devices, or structured tele-
phone support. More frequent monitoring may be required
during periods of instability or titration of medication, as well
as in older patients or those with important co-morbidities.
Particularly in recently discharged patients, optimal follow-
up decreases significantly readmission rates; the implementa-
tion of a 7 day follow-up visits programme in a tertiary US
hospital as a means of quality improvement resulted in a
30% decrease of HF 30 day readmission rate.13,14
Regular monitoring may detect disease progression and/or
complications or deterioration of symptoms that may require
a change in management (e.g. the onset of atrial fibrillation
or development of anaemia). Natriuretic peptides predict
outcome in this patient population; a decrease in their levels
during recovery from an episode of acute decompensation is
associated with better prognosis.15 Natriuretic peptide-
guided therapy has been proposed as a method to monitor
clinical status and tailor treatment; however, published stud-
ies have provided conflicting results, and this approach is not
recommended by the current guidelines.16
Telemedicine provides the possibility of remote patient as-
sessment. Several methods and technologies have been
tested; results of clinical trials are conflicting, but meta-
analyses suggest some clinical benefit.17
The recent ESC HF guidelines provide specific recommen-
dations regarding monitoring and follow-up of the patient
with HF, especially the elderly, encouraging physicians to
(i) monitor frailty and seek and address reversible causes
(cardiovascular and non-cardiovascular) of deterioration
in frailty score,
(ii) review medication and optimize doses of HF medication
slowly and with frequent monitoring of clinical status,
(iii) reduce polypharmacy (number, doses, and complexity of
regime),
(iv) consider stopping medication without an immediate ef-
fect on symptom relief or HR-QoL (such as statin),
(v) review the timing and dose of diuretic therapy to reduce
risk of incontinence, and
(vi) consider the need to refer to specialist care of the el-
derly team and to general practitioner and social worker,
for follow-up and support for the patient and his or her
family.16
The network may further provide consultation to patients
with a diagnosis of HF who are being treated and followed
outside the network, either on a regular basis or whenever
this is deemed necessary. In other words, the care of patients
may still remain with a treating physician outside the net-
work, and the patients may be reviewed in an HF clinic within
the network regularly or according to the needs.
Assessment of exercise capacity
Exercise intolerance is a main manifestation of HF directly re-
lated to the severity of the syndrome. Clinical variables and
The Task force of the Hellenic Heart Failure Clinics Network
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laboratory tests can be used to assess exercise intolerance.
The simplest method is the New York Heart Association
(NYHA) functional classification, which is based on patients’
symptoms. Decreased maximal exercise capacity is associated
with higher NYHA class and worse prognosis and quality of life.
Unfortunately, symptom severity poorly correlates with left
ventricular function and prognosis, and even patients with
mild symptoms bare a significant risk of morbidity and mortal-
ity.16,18 Furthermore, symptoms might reflect the severity of
other non-cardiovascular diseases and not HF per se. More
comprehensive questionnaires such as the Kansas City Cardio-
myopathy Questionnaire (KCCQ) that covers some very impor-
tant domains besides symptoms (i.e. self-efficacy, quality of
life, and social limitation) may add incremental value to NYHA
classification.19 The 6minwalk test is easy to implement, and it
can give objective information about patient’s exercise toler-
ance, especially in patients with severe symptoms, although
it may not discriminate accurately HF severity among asymp-
tomatic patients or those with mild symptoms.20 The best
method to assess functional capacity in HF patients is cardio-
pulmonary exercise stress test, as it provides accurate mea-
sures and prognostic parameters and may discriminate
between cardiac and non-cardiac causes of exercise intoler-
ance. However, the need for special equipment and experi-
enced personnel preclude its widespread use.18,21 In
conclusion, NYHA classification and 6 min walk test should be
implemented in all HF clinics, while the cardiopulmonary exer-
cise test should be available in more advanced setting.
Assessment of the health-related
quality of life
Heart failure patients generally report worse HR-QoL than the
general population or even patients with other chronic condi-
tions, such as diabetes mellitus, cancer, or Alzheimer’s dis-
ease.22 The term HR-QoL refers to the extent of a patient’s
general well-being, which is usually affected by the health
status. During the last years, the term disease-specific QoL
has been introduced and quantifies the limitation of a pa-
tient’s physical, emotional, and social life that can be attrib-
uted to a specific disease or syndrome.
The assessment of HR-QoL in HF patients includes HF-
specific self-administered questionnaires, namely, the Minne-
sota Living with Heart Failure Questionnaire and the
KCCQ.23,24 These questionnaires are easily completed, and
the results are summarized as functional, emotional, and
overall components. Both of them are widely accepted and
are proposed by the current European HF Guidelines, be-
cause they are excellent predictors of patients’ morbidity
and mortality.17 A shorter version of KCCQ is also available,25
while general quality of life questionnaires, such as the EQ-
5D26 may also be used.
Improving HR-QoL represents a stand-alone target in the
management of HF patients. Many recent large clinical trials
include improvement of QoL as an endpoint, moving towards
a more patient-centred approach. Thus, a combination of sur-
vival prolongation and QoL improvement, an outcome usually
estimated by the quality-adjusted life years, is increasingly
used by clinical trials.
The role of nurses
A holistic approach by an interdisciplinary team in all health
care settings, from primary to palliative, is needed for the ef-
fective management of HF.8,16 Nurses may have an important
role in such a comprehensive care. Prevention, early diagno-
sis of possible decompensation, and development of self-care
educational and follow-up programmes are key domains that
can be served by HF nurses, while they may act as care co-
ordinators and the liaison persons, who connect patients
and their family with the health care system.27,28 A recent
meta-analysis has shown that one of the determinants of a
successful HF management programme is whether HF nurses
were included in the programme.29 In addition, when post-
discharge follow-up programmes were led by nurses, a de-
crease in readmission rates was achieved.28 As the educa-
tional background of nurses involved in HF programmes is
pivotal, the HFA of the ESC has developed a curriculum for
HF nurses.30,31
Networking with primary and
community health care
While the acute phase of HF usually requires admission to
hospital for diagnostic interventions and treatment, the great
majority of patients live with chronic HF, and as the number
of these patients increases exponentially worldwide, out-of-
hospital community and primary care settings should be in-
volved in their care. Primary care services vary among coun-
tries and even within each country.
Prevention of HF and rapid referral to a cardiologist for di-
agnosis of HF in patients with symptoms are two aspects of
the disease to which primary care may contribute. Further-
more, there are multiple areas in HF management in which
primary care could play an important role32,33; education
and support of stable, low-risk patients and caregivers, pro-
motion of self-care, counselling on lifestyle modifications, ad-
herence to treatment and correct use of medications, and co-
ordination of care for co-morbidities. The 2016 ESC HF guide-
lines suggest that referral to primary care for long-term
follow-up may be considered for stable HF patients who are
on optimal therapy to monitor for effectiveness of treatment,
disease progression, and patient adherence (class IIb
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recommendation).16 Rigorous follow-up at periods of clinical
instability, that is, transition phase after hospital discharge,
and early identification of clinical worsening remain challeng-
ing areas in which primary care could offer great help. End-of-
life, palliative care, and home-care for frail patients unable to
move are also sensitive aspects of care.34
Although primary care physicians and nurses play a key
role in HF care,16 the current status of HF management in pri-
mary care remains suboptimal.34,35 Collaborative models of
care where the primary care physician may share the care
with a cardiologist have been shown to improve patient out-
comes compared with a primary physician only.36 Technology
may play a leading role in this regard, as telemedicine plat-
forms have been designed to link teams of experts within
an academic hub with primary care clinicians to improve care
provision and enhance primary physicians’ learning by provid-
ing mentoring and feedback from specialists.37 Therefore, de-
signing and establishing highly collaborative HF networks that
co-ordinate all groups involved in HF care provision at various
levels may improve HF patient outcomes and ensure that lim-
ited resources are effectively deployed.
Establishing proper communication among physicians, and
providing a clear patient pathway when required, is a crucial
need that an HF network should address and actually one of
the key reasons in building a network. Figure 1 provides an
idea of patient flow through the proposed three-level struc-
ture. In this context, establishing criteria for patient referral
is important, and this is an issue that this network will ad-
dress in the near future.
Training and accreditation in heart
failure
The complexity of HF syndrome dictates the need of training
and accreditation of physicians through a curriculum widely
accepted across Europe.2 HF subspecialty should be acknowl-
edged at a national level and offered as an additional option
of further training to cardiologists that express special inter-
est. The HFA of the ESC has provided a framework that can
be used as a blueprint and has defined the required knowl-
edge, the necessary skills, and the professionalism that
should be attained.38
The proposed programme of training in HF consists of two
12 month periods. The first period is dedicated to diagnosis
and investigation of HF, treatment of the underlying
aetiology, diagnosis and treatment of co-morbidities, medical
treatment of HF, lifestyle changes, device therapy for HF,
monitoring of HF patients, acute HF, and functioning as part
of multidisciplinary team. In the second period, HF specialist
trainee can choose between special modules and obtain fur-
ther expertise in advanced imaging (echocardiography and
cardiac magnetic resonance), device therapy, or heart trans-
plantation and mechanical circulation support. Finally, spe-
cific assessment methods of trainee’s knowledge, skills,
competence, and professionalism are mandatory and univer-
sally used: logbook for all procedures, direct observation of
procedural skills, assessment of behaviours in outpatient
and inpatient management, assessment of ability to function
in and lead a multidisciplinary team, overall management of
complex cases, participation in continuing medical education,
and assessment of advanced knowledge by online HFA educa-
tion programme with multiple choice questions. Subspecialty
HF accreditation programmes have been developed in US by
American Board of Internal Medicine39 and UK,40 and a
hands-on HF certification course is also provided by HFA.41
Heart failure-specific tools
Heart failure discharge note
Patients discharged with an HF diagnosis have a markedly
high readmission rate, reaching 30% at 3 months.42 In addi-
tion, readmission after index hospitalization carries a signifi-
cantly higher risk of mortality compared with index
hospitalization.43 Undoubtedly, the major issue with the most
widely used discharge notes is the lack of information on
post-discharge care transition and outpatient follow-up.44,45
In contrast, comprehensive discharge notes can significantly
reduce readmission rates.45–47 Discharge notes should consti-
tute a link between the patient, the hospital physicians, the
primary care and community physicians, and any other health
care professional involved in patient’s care. This will ensure
awareness of patient’s medical issues and assist in clinical de-
cision making with the ultimate goal of improving patient out-
comes and health care efficiency.47
A discharge note should contain information on diagnosis
and cause of HF; clinical status at admission (NYHA class);
Figure 1 A proposed scheme for the design of a heart failure care
network.
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echocardiographic findings and natriuretic peptide levels
confirming diagnosis; electrocardiogram mentioning QRS du-
ration, rhythm, presence of atrioventricular, bundle branch,
or fascicular block; laboratory tests results (urea, creatinine,
haemoglobin, BNP or NT-proBNP, and discharge electrolytes);
patient weight at discharge; blood pressure and heart rate at
discharge; medications and dosing during hospitalization and
discharge; titration instructions and reasons for use of smaller
target doses or document reason for no initiation; instruc-
tions concerning blood pressure, heart rate, and body weight
targets; arrhythmic risk stratification; programming for im-
plantation of a cardiac rhythm management device;
encouragement for daily monitoring of body weight;
smoking cessation and referral to specialized centres;
targeted dietary instructions; administration and monitoring
of anticoagulation therapy, on indication, as well as cautions
for co-administration with certain medications (antibiotics)
and annual flu vaccination. The components of an HF dis-
charge note are outlined in Table 2.
Heart failure patient booklet and information
leaflet
The recent European HF Guidelines suggest that a ‘seamless’
system of health care for patients leaving hospital and
returning to the community is key to success.16 In this con-
text, an HF patient booklet is a means to improve medical
management, access to care during episodes of decompensa-
tion, follow-up after discharge, patient education, and treat-
ment adherence. Such a booklet should offer an integrated
and comprehensive view of administrative and health-related
information as outlined in Table 3. The booklet may be deliv-
ered in a hard copy paper format, while a printed
Table 2 Components of a structured heart failure-specific discharge note
• Demographics and administrative data
• Diagnosis and cause of heart failure
• Clinical status at admission (NYHA class)
• Echocardiographic findings and natriuretic peptide levels confirming diagnosis
• Copy of an electrocardiogram mentioning QRS duration, rhythm, presence of atrioventricular or bundle branch, or fascicular block
• Laboratory tests results (urea, creatinine, haemoglobin, BNP or NT-proBNP, and discharge electrolytes)
• Patient weight at discharge (‘dry weight’)
• Blood pressure and heart rate at discharge
• Medications and dosing during hospitalization and following discharge. If no beta-blockers, MRAs, ACEIs, or, alternatively, ARBs are
administered record and document reason
• Titration instructions and reasons for use of smaller target doses
• Instructions concerning blood pressure, heart rate, and body weight targets
• Arrhythmic risk stratification and, on indications, programming for implantation of a cardiac rhythm management device (defibrillator,
biventricular pacemaker)
• Encouragement for daily monitoring of body weight and, in case of abrupt increase—more than 2 kg in 3 days, contact with treating
physician
• Encouragement for smoking cessation and referral to specialized centres
• Targeted dietary instructions
• Instructions for administration and monitoring of anticoagulation therapy, on indications, as well as cautions for co-administration
with certain medications (antibiotics)
• Instructions for annual flu vaccination
• Instructions for reassessment at a dedicated heart failure outpatient clinic following a laboratory workup (which should be detailed)
• Names of treating physicians, with attached copies of their instructions
• Patient information regarding contact details for Heart Failure Outpatient Clinic, both of the discharging hospital and hospitals
near patient’s residence
Table 3 Components of a heart failure patient booklet
• Personal data, family and social history, contact details
• Past medical history, co-morbidities, surgeries and other procedures, allergies and adverse drug reactions, blood transfusions
• HF aetiology, disease course, phenotype, device therapy, hospitalizations for decompensation
• A review of medications and dosing, including possible side effects, need for changes and up-titration goals
• A clinical assessment of vital signs, cardiac rhythm, functional capacity, 6 min walk test, fluid status, nutritional and cognitive status
• Reports of imaging (echocardiography, chest X-ray, SPECT, coronary angiography, cardiac ΜRΙ), cardiorespiratory stress test with VO2
max, electrophysiology study and ablation, myocardial biopsy, genetic testing
• Laboratory test results (serum urea, creatinine, electrolytes, haemoglobin, ferritin, TSH, NT proBNP)
• Vaccinations
• Consultation of other specialists
• Free space for special notes
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electrocardiogram and copies of clinic notes may be parts of
it, and data can be updated at follow-up consultations. Used
as a hand-held tool during patient review, the booklet may
rapidly inform the health care professional about the key fea-
tures of the HF patient, which are required to optimize care.
In addition to an HF patient booklet, a patient information
leaflet, containing all important pieces of information that the
patient should know about HF, is useful. Written in simple
language, this leaflet would provide a reliable source of infor-
mation to address the needs of the broad spectrum of HF pa-
tients, including not only those with poor access to sources of
knowledge, such as elderly people, but also those that are ex-
posed to a wealth of information that may sometimes be
unreliable and misleading. The proposed components of this
leaflet are summarized in Table 4, while a complete
example of such a leaflet can be found in Supporting Informa-
tion, Data S1.
Continuous patient education remains an important aim of
this network. Besides the HF patient booklet and the informa-
tional leaflet, important information for patient guidance is
also included in the HF-specific discharge note, as previously
mentioned. In addition to provided knowledge, the patient
leaflet encourages the patients to seek further knowledge in
suggested Internet resources, such as the webpage hosting
the Greek translation of the ‘Heart Failure Matters’ project.
HF classes for patients and other educational events are fur-
ther encouraged and supported by the network, but they de-
pend upon local potentials. Besides these modalities, patient
education remains a continuous process that should ideally
occur during every contact with the physician.
Heart failure e-platform
The management of HF is characterized by lifelong care,
with multiple outpatient clinic visits, frequent hospital ad-
missions, and multidisciplinary care with visits to other med-
ical specialists. This creates a bulk of medical information
with huge medical records that are not able to handle in
paper. As a result, HF management imposes the use of elec-
tronic medical records. In addition, an indispensable part of
an HF network is research activities. Actually, HF networks
are ideal for generation of real-world evidence that can be
used for the identification of unmet health care needs, the
design of public health policies, or the documented advo-
cacy for health system reforms as well as for participation
in clinical research projects.48 Exploitation of HF patient
data for research requires the development of a well-
organized medical database that cannot be performed with-
out a proper electronic platform. An electronic platform
that would combine the aforementioned functions would
be ideal for the needs of an HF network. The features of
such a platform include a well-structured and functional
medical record for outpatient and inpatient contacts, the
widest possible accessibility from inside and outside the
medical units, which can be provided only by a web-based
platform, the possibility of multiple simultaneous users,
the extraction of anonymized data for research use, the
possibility of customization for special clinical or research
purposes, and a high-level data safety with the use of se-
cure data servers and proper encryption algorithms in ac-
cordance with the international standards. Additional
features could render the system more attractive for clini-
cians, such as the generation of automated documents like
prescription or an appointment support system. In addition,
Table 4 Components of a heart failure patient information leaflet
• What is heart failure?










• How do I deal with emotions and feelings?
• How should I assess and manage my condition?
•What kind of services are provided by the heart failure clinics, and
why should I attend one?
• Where can I find more information (websites)?
Table 5 Main features of an electronic platform for heart failure
networks
e-platform features
• Structured HF-specific electronic medical record
• Extractable anonymized datasets for research exploitation
•Wide accessibility form inside and outside medical units—web-
based
• Multiple simultaneous users
• Customization for clinical or research purposes
• Automatic document generation (e.g. discharge note and
prescriptions)
• Appointment support system
• Established data safety protocols
• Secured data server complying with international standards
Medical record structure
















- Next appointment data and time
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the e-platform supports the development of fully customiz-
able dedicated data entry forms that can be used to host
surveys and registries. The features and structure of an
HF-specific electronic platform are summarized in Table 5.
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